Jazz Pharmaceuticals Submits New Drug Application for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnea

DUBLIN, Dec. 21, 2017 -- (Healthcare Sales & Marketing Network) -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration on December 20, 2017 seeking marketing appro... Biopharmaceuticals, FDA Jazz Pharmaceuticals, solriamfetol, narcolepsy, obstructive sleep apnea
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news